Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 8, 2005
Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferaseWenqing Gao, Jeffrey S Johnston, Duane D Miller, et al.American Journal of Pharmaceutical Education|July 1, 2009
A genotyping exercise for pharmacogenetics in pharmacy practiceDaren L Knoell, Jeffrey S Johnston, Shengying Bao, et al.Pharmaceutical Research|July 26, 2003
Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cellsJeffrey S Johnston, Andrew Johnson, Yuebo Gan, et al.Pharmaceutical Research|April 23, 2005
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitorsSean Ekins, Jeffrey S Johnston, Praveen Bahadduri, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 19, 2008
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaJeffrey S Johnston, Mitch A Phelps, Kristie A Blum, et al.Cancer|September 20, 2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaRobert A Baiocchi, Lapo Alinari, Mark E Lustberg, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 21, 2008
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing scheduleMitch A Phelps, Darlene M Rozewski, Jeffrey S Johnston, et al.Clinical Pharmacokinetics|April 17, 2013
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host diseaseMing J Poi, Craig C Hofmeister, Jeffrey S Johnston, et al.Leukemia & Lymphoma|December 22, 2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca Klisovic, Jeffrey S Johnston, et al.Mabs|January 5, 2010
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaLapo Alinari, Valerie L White, Christian T Earl, et al.Pageof 1